	Company Name	Product Name	Treatment Area	Phase	Mechanism of Action	Pipeline/PDF Url	Flags
0	biogen	obinutuzumab.	['disease']	False	['humanized antibody']	https://www.biogen.com/en_us/research-pipeline/biogen-pipeline.html	[]
1	biogen	BG00011	['fibrosis', 'Pulmonary', 'disease', 'pulmonary', 'Idiopathic', 'brain']	2	[]	https://www.biogen.com/en_us/research-pipeline/biogen-pipeline.html	[]
2	biogen	BG00011	['fibrosis']	2	['antibody']	https://www.biogen.com/en_us/research-pipeline/biogen-pipeline.html	[]
3	biogen	natalizumab	[]	2	['humanized antibody']	https://www.biogen.com/en_us/research-pipeline/biogen-pipeline.html	[]
4	biogen	BACE1	"[""Alzheimer's"", 'disease', 'common']"	False	[]	https://www.biogen.com/en_us/research-pipeline/biogen-pipeline.html	[]
5	biogen	BAN2401	['disease', 'loss', 'brain', 'common']	2	['mAb)']	https://www.biogen.com/en_us/research-pipeline/biogen-pipeline.html	[]
6	biogen	BAN2401	['brain']	2	['antibody']	https://www.biogen.com/en_us/research-pipeline/biogen-pipeline.html	[]
7	biogen	BIIB074	['disease', 'lupus']	2	['inhibitor)']	https://www.biogen.com/en_us/research-pipeline/biogen-pipeline.html	[]
8	biogen	BIIB074	[]	2	['inhibitor)']	https://www.biogen.com/en_us/research-pipeline/biogen-pipeline.html	[]
9	biogen	BIIB074	[]	2	[]	https://www.biogen.com/en_us/research-pipeline/biogen-pipeline.html	[]
10	biogen	rituximab	['A', 'Sclerosis']	False	['Chimeric antibody']	https://www.biogen.com/en_us/research-pipeline/biogen-pipeline.html	[]
11	biogen	aducanumab	"['disease', ""Alzheimer's""]"	3	[]	https://www.biogen.com/en_us/research-pipeline/biogen-pipeline.html	[]
12	biogen	BIIB054	"[""Parkinson's"", 'disease']"	2	[]	https://www.biogen.com/en_us/research-pipeline/biogen-pipeline.html	[]
13	biogen	BIIB054	"[""Parkinson's""]"	2	[]	https://www.biogen.com/en_us/research-pipeline/biogen-pipeline.html	[]
14	biogen	BIIB059	['fibrosis', 'chronic', 'disease', 'lupus', 'Lupus', 'brain', 'inflammatory']	2	[]	https://www.biogen.com/en_us/research-pipeline/biogen-pipeline.html	[]
15	biogen	Aducanumab	['disease', 'loss', 'brain', 'common']	3	['mAb)']	https://www.biogen.com/en_us/research-pipeline/biogen-pipeline.html	[]
16	biogen	Aducanumab	[]	3	['antibody']	https://www.biogen.com/en_us/research-pipeline/biogen-pipeline.html	[]
17	biogen	BIIB067	"['common', 'disease', 'sclerosis', 'loss', ""Parkinson's"", 'brain', 'ALS']"	2	[]	https://www.biogen.com/en_us/research-pipeline/biogen-pipeline.html	[]
18	biogen	BIIB067	['ALS']	2	[]	https://www.biogen.com/en_us/research-pipeline/biogen-pipeline.html	[]
19	biogen	fampridine	[]	False	['chemical substance']	https://www.biogen.com/en_us/research-pipeline/biogen-pipeline.html	[]
20	biogen	daclizumab	[]	False	['humanized antibody']	https://www.biogen.com/en_us/research-pipeline/biogen-pipeline.html	[]
21	biogen	obinutuzumab	[]	3	['humanized antibody']	https://www.biogen.com/en_us/research-pipeline/biogen-pipeline.html	[]
22	biogen	obinutuzumab	['cancer']	3	['humanized antibody']	https://www.biogen.com/en_us/research-pipeline/biogen-pipeline.html	[]
23	biogen	Infliximab	[]	False	['Chimeric antibody']	https://www.biogen.com/en_us/research-pipeline/biogen-pipeline.html	[]
24	biogen	Dapirolizumab	['chronic', 'B', 'disease', 'Lupus', 'brain', 'inflammatory']	2	['humanized antibody']	https://www.biogen.com/en_us/research-pipeline/biogen-pipeline.html	[]
25	biogen	Dapirolizumab	['disease', 'lupus']	2	['antibody']	https://www.biogen.com/en_us/research-pipeline/biogen-pipeline.html	[]
26	biogen	Natalizumab	['stroke', 'Stroke', 'ischemic', 'disease', 'sclerosis', 'lupus', 'acute', 'Acute', 'Crohn’s']	2	['inhibitor)']	https://www.biogen.com/en_us/research-pipeline/biogen-pipeline.html	[]
27	biogen	Natalizumab	['inflammatory', 'lymphocytic', 'brain', 'acute']	2	['humanized antibody']	https://www.biogen.com/en_us/research-pipeline/biogen-pipeline.html	[]
28	biogen	E2609	"['disease', 'loss', ""Alzheimer's"", 'brain', 'common']"	3	['(BACE1', 'inhibitor)']	https://www.biogen.com/en_us/research-pipeline/biogen-pipeline.html	[]
29	biogen	E2609	[]	3	['inhibitor']	https://www.biogen.com/en_us/research-pipeline/biogen-pipeline.html	[]
30	biogen	E2609	['non-Hodgkin’s']	3	[]	https://www.biogen.com/en_us/research-pipeline/biogen-pipeline.html	[]
31	biogen	Opicinumab	['disease', 'sclerosis', 'loss', 'vision', 'virus']	2	[]	https://www.biogen.com/en_us/research-pipeline/biogen-pipeline.html	[]
32	biogen	Obinutuzumab	['chronic', 'lymphoma', 'tumors', 'lymphocytic', 'non-Hodgkin’s', 'cancer', 'B']	3	['humanized antibody']	https://www.biogen.com/en_us/research-pipeline/biogen-pipeline.html	[]
33	biogen	Obinutuzumab	[]	3	['antibody']	https://www.biogen.com/en_us/research-pipeline/biogen-pipeline.html	[]
34	tevapharm	TEV-90105	['Disease', 'syndrome', 'Schizophrenia', 'Tourette']	3	[]	/files/pipeline/Public_pipeline_Feb2017.pdf	['PDF link provided']
35	tevapharm	Deutetrabenazine	['Huntington', 'Disease', 'Asthma', 'Asthma']	False	[]	/files/pipeline/Public_pipeline_Feb2017.pdf	['PDF link provided']
36	tevapharm	TV-46000	['Disease']	1	[]	/files/pipeline/Public_pipeline_Feb2017.pdf	['PDF link provided']
37	tevapharm	SD-809	['syndrome', 'Tourette']	3	[]	/files/pipeline/Public_pipeline_Feb2017.pdf	['PDF link provided']
38	tevapharm	SD-809	['Huntington']	1	[]	/files/pipeline/Public_pipeline_Feb2017.pdf	['PDF link provided']
39	tevapharm	SD-809	['Asthma']	1	[]	/files/pipeline/Public_pipeline_Feb2017.pdf	['PDF link provided']
40	tevapharm	Fasinumab	['Chronic']	1	[]	/files/pipeline/Public_pipeline_Feb2017.pdf	['PDF link provided']
41	tevapharm	Fasinumab	['Osteoarthritis']	1	[]	/files/pipeline/Public_pipeline_Feb2017.pdf	['PDF link provided']
42	tevapharm	SD-1077	['syndrome', 'Tourette']	3	[]	/files/pipeline/Public_pipeline_Feb2017.pdf	['PDF link provided']
43	tevapharm	Laquinimod	['Chronic']	2	[]	/files/pipeline/Public_pipeline_Feb2017.pdf	['PDF link provided']
44	tevapharm	Laquinimod	['Huntington']	2	[]	/files/pipeline/Public_pipeline_Feb2017.pdf	['PDF link provided']
45	tevapharm	Laquinimod	['Osteoarthritis', 'sclerosis']	2	[]	/files/pipeline/Public_pipeline_Feb2017.pdf	['PDF link provided']
46	tevapharm	migraine(Global	['Huntington', 'Disease', 'Chronic', 'Osteoarthritis']	False	[]	/files/pipeline/Public_pipeline_Feb2017.pdf	['PDF link provided']
47	tevapharm	TV-46139	['syndrome', 'Tourette']	3	[]	/files/pipeline/Public_pipeline_Feb2017.pdf	['PDF link provided']
48	tevapharm	Pridopidine	['Huntington', 'Disease']	2	['chemical substance']	/files/pipeline/Public_pipeline_Feb2017.pdf	['PDF link provided']
49	tevapharm	CT-P6	['Disease', 'Huntington', 'Asthma']	3	[]	/files/pipeline/Public_pipeline_Feb2017.pdf	['PDF link provided']
50	tevapharm	Reslizumab*	['sclerosis', 'Asthma']	3	['humanized antibody']	/files/pipeline/Public_pipeline_Feb2017.pdf	['PDF link provided']
51	tevapharm	Reslizumab*	['Sclerosis', 'Asthma']	3	['humanized antibody']	/files/pipeline/Public_pipeline_Feb2017.pdf	['PDF link provided']
52	tevapharm	CT-P10	['Asthma']	3	[]	/files/pipeline/Public_pipeline_Feb2017.pdf	['PDF link provided']
53	tevapharm	TV-45070	['Schizophrenia']	2	[]	/files/pipeline/Public_pipeline_Feb2017.pdf	['PDF link provided']
54	tevapharm	TV-46763	['Osteoarthritis', 'sclerosis']	3	[]	/files/pipeline/Public_pipeline_Feb2017.pdf	['PDF link provided']
55	tevapharm	Fremanezumab	['Huntington', 'Disease']	3	['humanized antibody']	/files/pipeline/Public_pipeline_Feb2017.pdf	['PDF link provided']
56	tevapharm	Fremanezumab	['Chronic', 'Huntington', 'Disease']	3	['humanized antibody']	/files/pipeline/Public_pipeline_Feb2017.pdf	['PDF link provided']
57	tevapharm	Fremanezumab	['Osteoarthritis', 'Chronic', 'Disease']	3	['humanized antibody']	/files/pipeline/Public_pipeline_Feb2017.pdf	['PDF link provided']
58	shire	SHP656	['Hemophilia', 'A']	3	[]	https://www.shire.com/research-and-development/pipeline	[]
59	shire	SHP611	['Genetic', 'Diseases']	3	[]	https://www.shire.com/research-and-development/pipeline	[]
60	shire	BAX930	['A', 'Hemophilia']	1	[]	https://www.shire.com/research-and-development/pipeline	[]
61	shire	SHP465	['Oncology', 'ADHD', 'Chronic', 'Constipation']	3	[]	https://www.shire.com/research-and-development/pipeline	[]
62	shire	SHP621	['Oncology']	3	[]	https://www.shire.com/research-and-development/pipeline	[]
63	shire	SHP652	['Lupus', '(SLE)']	3	[]	https://www.shire.com/research-and-development/pipeline	[]
64	shire	BAX826	['Willebrand', 'ADHD', 'Disease']	1	[]	https://www.shire.com/research-and-development/pipeline	[]
65	shire	SHP607	"['Ataxia', 'Diseases', 'Genetic', 'Oncology', ""Friedreich's"", 'CMV']"	2	[]	https://www.shire.com/research-and-development/pipeline	[]
66	shire	SHP643	['Genetic', 'Diseases']	3	[]	https://www.shire.com/research-and-development/pipeline	[]
67	shire	SM101	['(SLE)']	1	[]	https://www.shire.com/research-and-development/pipeline	[]
68	shire	SHP620	['CMV', 'Oncology']	3	[]	https://www.shire.com/research-and-development/pipeline	[]
69	shire	SHP647	['Ulcerative']	3	[]	https://www.shire.com/research-and-development/pipeline	[]
70	shire	SHP640	['Genetic', 'Diseases']	2	[]	https://www.shire.com/research-and-development/pipeline	[]
71	shire	SHP609	['Genetic', 'Diseases']	3	[]	https://www.shire.com/research-and-development/pipeline	[]
72	shire	SHP631	['Genetic', 'Diseases']	1	[]	https://www.shire.com/research-and-development/pipeline	[]
73	shire	SHP622	"[""Friedreich's"", 'Ataxia']"	1	[]	https://www.shire.com/research-and-development/pipeline	[]
74	shire	SHP626	[]	2	[]	https://www.shire.com/research-and-development/pipeline	[]
75	shire	SHP555	['ADHD', 'Chronic', 'Constipation']	3	[]	https://www.shire.com/research-and-development/pipeline	[]
76	shire	SHP655	[]	1	[]	https://www.shire.com/research-and-development/pipeline	[]
77	shire	SHP625	['Syndrome']	2	[]	https://www.shire.com/research-and-development/pipeline	[]
78	shire	SHP623	['Ulcerative', 'Diseases', 'Genetic', 'Lupus', '(SLE)', 'Syndrome']	1	[]	https://www.shire.com/research-and-development/pipeline	[]
79	novartis	AMG334	['Migraine', 'acute']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
80	novartis	GP1111	['anemia', 'Autoimmune', 'kidney', 'rheumatoid', 'arthritis']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
81	novartis	QBW251	['fibrosis', 'tumors']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
82	novartis	BYM338	['disease', 'disorders']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
83	novartis	BYM338	['dermatitis']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
84	novartis	GP2018	['Autoimmune', 'rheumatoid', 'arthritis', 'cancer']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
85	novartis	VAY736	['syndrome']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
86	novartis	QAW039	['Heart', 'lymphoma', 'Asthma', 'disease', 'Acute']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
87	novartis	QAW039	['Acute', 'dermatitis']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
88	novartis	CNP520	['disease', 'disorders']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
89	novartis	QMF149	['Asthma', 'tumors']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
90	novartis	LJN452	['loss']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
91	novartis	INC280	['sclerosis', 'cancer']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
92	novartis	INC280	['cancer']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
93	novartis	RTH258	['disease']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
94	novartis	RTH258	['disease', 'Chronic', 'myelofibrosis']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
95	novartis	HX575	['Chronic', 'psoriasis', 'anemia', 'kidney']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
96	novartis	adalimumab	['disease', 'Chronic', 'arthritis', 'myelofibrosis']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
97	novartis	adalimumab	['cancer', 'breast', 'dermatitis']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
98	novartis	UNR844	['fibrosis']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
99	novartis	PDR001	['lymphoma', 'Asthma', 'breast', 'cancer']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
100	novartis	PDR001	['sclerosis']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
101	novartis	LA-EP2006	['rheumatoid', 'arthritis']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
102	novartis	LCI699	['disease', 'cancer']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
103	novartis	CJM112	['disease', 'disorders']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
104	novartis	ACZ885	['acute']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
105	novartis	ABL001	['Chronic']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
106	novartis	OMB157	['disease', 'sclerosis', 'Acute']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
107	novartis	CAD106	['disease']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
108	novartis	ECF843	['eye', 'disease']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
109	novartis	KAE609	['disease', 'eye', 'loss']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
110	novartis	BAF312	['sclerosis']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
111	novartis	BYL719	['breast', 'cancer']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
112	novartis	PKC412	['breast', 'Acute', 'cancer']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
113	novartis	QGE031	['Chronic', 'arthritis', 'chronic']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
114	novartis	CTL019	['acute']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
115	novartis	CTL019	['lymphoma']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
116	novartis	Neuroendocrine	['tumors']	False	['chemical substance']	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
117	novartis	EMA401	['eye']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
118	novartis	GP2013	['rheumatoid', 'B', 'chronic', 'lymphocytic']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
119	novartis	QVM149	['Asthma', 'cancer']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
120	novartis	SEG101	['disease', 'Sickle']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
121	novartis	LIK066	['loss']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
122	novartis	PIM447	['tumors']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
123	novartis	LAM320	['breast', 'tuberculosis', 'disease', 'Sickle', 'cancer']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
124	novartis	KAF156	['eye', 'loss', 'tumors']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
125	novartis	GP2017	['disease', 'psoriasis']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
126	novartis	FTY720	['lymphoma', 'sclerosis', 'anemia']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
127	novartis	ZPL389	['syndrome', 'dermatitis']	False	[]	https://www.novartis.com/sites/www.novartis.com/files/novartis-pipeline-2016-annual-report.pdf	['PDF link provided', 'Data is not up to accuracy standards: 0']
128	pfizer	IRAK4	['Rheumatoid']	3	[]	/sites/default/files/product-pipeline/013117-Pipeline-Update.pdf	['PDF link provided']
129	pfizer	Avelumab	['Breast', 'Diabetes', 'Sickle', 'Ovarian', 'Deficiency', 'Cancer']	3	[]	/sites/default/files/product-pipeline/013117-Pipeline-Update.pdf	['PDF link provided']
130	pfizer	lorlatinib	['Arthritis', 'Deficiency', 'Cancer', 'Rheumatoid']	False	['tyrosine-kinase inhibitor']	/sites/default/files/product-pipeline/013117-Pipeline-Update.pdf	['PDF link provided']
131	pfizer	Tanezumab	['Sickle', 'Disease', 'Breast', 'Cancer', 'OA', 'Chronic', 'Cancer', 'Meningococcal']	False	[]	/sites/default/files/product-pipeline/013117-Pipeline-Update.pdf	['PDF link provided']
132	pfizer	meglumine	['Cancer', 'Meningococcal', 'B', 'Ulcerative', 'Arthritis', 'Breast', 'Prostate', 'Cancer']	False	[]	/sites/default/files/product-pipeline/013117-Pipeline-Update.pdf	['PDF link provided']
133	pfizer	talazoparib	['Sickle', 'Disease', 'Breast']	3	['PARP inhibitor']	/sites/default/files/product-pipeline/013117-Pipeline-Update.pdf	['PDF link provided']
134	ionis	ionis	['!']	['!']	['!']	http://www.ionispharma.com/pipeline/	['Error attempting to reach website!']
135	roche	bevacizumab	['A']	1	['antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
136	roche	bevacizumab	['tumor']	3	['monoclonal', 'antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
137	roche	bevacizumab	['ovarian', 'tumor']	1	['monoclonal']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
138	roche	bevacizumab	['Oncology']	1	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
139	roche	alectinib	['Cancer']	1	['tyrosine-kinase inhibitor']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
140	roche	alectinib	['Oncology']	3	['tyrosine-kinase inhibitor']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
141	roche	RG7880	['inflammatory']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
142	roche	RG6107	[]	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
143	roche	RG6107	[]	1	['inhibitor', 'monoclonal']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
144	roche	RG6107	['lymphoma']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
145	roche	RG7893	['aureus', 'ovarian', 'Diseases', 'HIV', 'HPV', 'MRSA', 'Staphylococcus', 'tumor', 'Oncology', 'cancer', 'Cervical', 'Cancer', 'infection', 'acute']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
146	roche	RG7986	['B', 'Oncology', 'lymphoma']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
147	roche	ARN-810	['breast', 'cancer']	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
148	roche	CKI27	['Oncology', 'tumors']	3	['MEK', 'inhibitor']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
149	roche	polatuzumab	['tumor', 'conjugate']	2	['antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
150	roche	tocilizumab	['sclerosis']	3	['monoclonal']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
151	roche	tocilizumab	['vasculitis']	3	['monoclonal', 'antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
152	roche	tocilizumab	[]	3	['monoclonal']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
153	roche	RG7802	['Oncology', 'tumors']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
154	roche	RG7802	['tumor', 'tumors']	1	['antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
155	roche	RG7802	['tumor']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
156	roche	RG7625	['autoimmune']	2	['antagonist']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
157	roche	RG7440	['breast', 'Oncology']	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
158	roche	RG7440	['Oncology', 'cancer', 'prostate']	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
159	roche	RG7440	['cancer', 'breast', 'tumours']	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
160	roche	RG7440	['breast']	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
161	roche	trastuzumab-DM1	['breast', 'Oncology', 'cancer']	3	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
162	roche	trastuzumab-DM1	['breast', 'cancer']	3	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
163	roche	danoprevir	['hepatitis']	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
164	roche	RG7828	['Oncology', 'tumours']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
165	roche	codrituzumab	['liver', 'cancer']	2	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
166	roche	CSF-1	['A']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
167	roche	CSF-1	[]	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
168	roche	ranibizumab	[]	2	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
169	roche	ranibizumab	[]	3	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
170	roche	ranibizumab	['Diseases']	2	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
171	roche	RG7155+RG7876	['Oncology']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
172	roche	RG7314	['autism']	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
173	roche	RG7314	['autism', 'Autism']	2	['antagonist']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
174	roche	RG7907	['B', 'hepatitis', 'infection', 'Diseases']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
175	roche	RG7907	['B', 'hepatitis', 'infection']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
176	roche	RG6061	['Oncology', 'tumors']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
177	roche	RG6061	['tumors']	1	['oligonucleotide', 'oligonucleotide']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
178	roche	RG7992	[]	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
179	roche	RG7992	['gout']	1	['antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
180	roche	RG7800	['A', 'atrophy']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
181	roche	Danoprevir	['hepatitis']	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
182	roche	RG6000	['amyotrophic', 'sclerosis']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
183	roche	RG6000	['sclerosis', 'amyotrophic']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
184	roche	etrolizumab	['ulcerative']	3	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
185	roche	etrolizumab	['disease']	3	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
186	roche	Atezolizumab	['A', 'cancer']	1	['monoclonal', 'antibody', 'PD-L1']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
187	roche	Atezolizumab	['cancer']	1	['monoclonal', 'antibody', 'PD-L1']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
188	roche	Atezolizumab	['breast', 'cancer']	3	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
189	roche	Atezolizumab	['tumours', 'cancer']	3	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
190	roche	Atezolizumab	['cancer']	3	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
191	roche	Atezolizumab	['Oncology', 'cancer']	3	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
192	roche	RG7159	['Oncology']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
193	roche	RG7159	['disease']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
194	roche	RG7159	['lupus']	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
195	roche	RG7159	['lymphoma']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
196	roche	RG105	['Oncology']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
197	roche	RG105	[]	3	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
198	roche	RG7841	['breast', 'cancer']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
199	roche	RG3645	[]	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
200	roche	RG3645	[]	3	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
201	roche	RG3645	['vasculitis']	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
202	roche	RG3645	['cancer']	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
203	roche	RG7386	['Oncology', 'tumours']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
204	roche	RG7386	['tumour', 'tumours']	1	['antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
205	roche	RG7386	['tumour-cell']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
206	roche	obinutuzumab	['Oncology']	1	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
207	roche	obinutuzumab	['Cancer', 'lymphoma']	1	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
208	roche	obinutuzumab	['lymphoma']	1	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
209	roche	obinutuzumab	['disease']	1	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
210	roche	obinutuzumab	['A']	1	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
211	roche	obinutuzumab	['lupus']	2	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
212	roche	obinutuzumab	['A', 'lupus']	2	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
213	roche	BRAFv600	['A']	3	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
214	roche	BRAFv600	['lymphoma']	3	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
215	roche	RG6114	['breast', 'Oncology', 'cancer']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
216	roche	RG6114	['breast', 'cancer']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
217	roche	RG6114	['tumours', 'breast', 'cancer']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
218	roche	RG6083	['atrophy']	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
219	roche	Nav1.7	['peripheral']	False	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
220	roche	atezolizumab.	['Oncology']	1	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
221	roche	RG1662	['A', 'disorders', 'brain']	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
222	roche	RG7882	['ovarian', 'A', 'Oncology', 'cancer']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
223	roche	RG7882	['ovarian', 'cancer', 'conjugate']	1	['antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
224	roche	RG7446	['Oncology']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
225	roche	RG7446+ipilimumab	['Oncology']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
226	roche	RG7446	['tumors']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
227	roche	RG7446	['Oncology']	3	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
228	roche	RG7446	['breast']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
229	roche	RG7446	['cancer', 'prostate']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
230	roche	RG3637	['fibrosis', 'idiopathic', 'pulmonary']	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
231	roche	RG3637	['dermatitis', 'pulmonary']	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
232	roche	RG3637	['disease', 'chronic', 'pulmonary']	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
233	roche	RG7221	['Oncology']	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
234	roche	RG3616	['myelofibrosis']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
235	roche	RG3616	['fibrosis', 'idiopathic', 'A', 'pulmonary']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
236	roche	RG7204	['Oncology']	3	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
237	roche	ruxolitinib	['fibrosis', 'A', 'myelofibrosis']	1	['tyrosine-kinase inhibitor']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
238	roche	ruxolitinib	['A']	1	['inhibitor']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
239	roche	GDC-0199	[]	3	['Bcl-2', 'inhibitor']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
240	roche	nemolizumab	['dermatitis']	2	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
241	roche	nemolizumab	[]	2	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
242	roche	lampalizumab	['atrophy']	3	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
243	roche	FPI-1459	['Diseases']	1	['inhibitor']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
244	roche	RG7421	['Oncology']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
245	roche	RG7421	['Oncology']	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
246	roche	RG7421	['Oncology']	3	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
247	roche	RG7421	['cancer', 'prostate']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
248	roche	emactuzumab	['Cancer', 'tumors']	1	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
249	roche	emactuzumab	['A']	1	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
250	roche	emactuzumab+atezolizumab	['Cancer', 'Oncology', 'tumors']	1	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
251	roche	emactuzumab	['A', 'cancer']	1	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
252	roche	RG6149	['asthma']	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
253	roche	RG6149	['asthma']	2	['monoclonal', 'antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
254	roche	RG6100	"['disease', ""Alzheimer's""]"	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
255	roche	Emactuzumab	[]	1	['monoclonal', 'antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
256	roche	lebrikizumab	['fibrosis', 'idiopathic', 'pulmonary']	2	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
257	roche	lebrikizumab	['dermatitis']	2	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
258	roche	lebrikizumab	['disease', 'chronic', 'pulmonary']	2	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
259	roche	lebrikizumab	['A', 'chronic', 'pulmonary']	2	['cytokine']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
260	roche	ocrelizumab	['sclerosis']	1	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
261	roche	Alectinib	['lymphoma']	3	['tyrosine-kinase inhibitor']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
262	roche	Alectinib	['disease', 'malignant', 'tumorigenesis']	3	['tyrosine-kinase inhibitor']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
263	roche	Gantenerumab	"['disease', ""Alzheimer's"", 'brain']"	3	['monoclonal', 'antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
264	roche	ipilimumab	['Cancer', 'Oncology', 'tumors']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
265	roche	ipilimumab	['tumours']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
266	roche	RG7888	['Cancer', 'Oncology', 'tumors']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
267	roche	RG7888	[]	1	['monoclonal']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
268	roche	RG7888+atezolizumab	['Oncology']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
269	roche	RG7888	['A']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
270	roche	RG6046	['breast', 'Oncology', 'cancer']	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
271	roche	RG6046	['breast', 'cancer']	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
272	roche	erlotinib	['Oncology']	1	['tyrosine-kinase inhibitor']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
273	roche	RG435	['Oncology']	3	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
274	roche	RG7716	[]	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
275	roche	RG7716	['A']	2	['antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
276	roche	RG7745	['A', 'Diseases', 'influenza']	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
277	roche	RG7745	['A', 'virus', 'influenza']	2	['monoclonal', 'antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
278	roche	RG7745	['A', 'influenza']	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
279	roche	RG7845	['autoimmune']	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
280	roche	emtansine	['breast']	2	['chemical substance']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
281	roche	emtansine	['conjugate']	3	['chemical substance']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
282	roche	emtansine+pertuzumab	['breast', 'Oncology']	3	['chemical substance']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
283	roche	RG7417	['atrophy']	3	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
284	roche	RG7813	['Oncology', 'tumors']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
285	roche	RG7813	['tumors']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
286	roche	RG7813	['A', 'tumors']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
287	roche	RG7813+RG7446	['Oncology']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
288	roche	RG7813	[]	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
289	roche	RG7834	['B', 'hepatitis', 'chronic', 'Diseases']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
290	roche	Vanucizumab	['cancer']	2	['monoclonal', 'antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
291	roche	Angiopoietin-2	[]	3	['antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
292	roche	RG6069	['fibrosis']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
293	roche	RG7388	['Oncology', 'acute']	3	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
294	roche	RG7596	['Oncology']	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
295	roche	Trastuzumab	['breast', 'cancer']	3	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
296	roche	Trastuzumab	['breast']	3	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
297	roche	RG6078	['Cancer', 'Oncology', 'tumors']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
298	roche	RG6078	['cancer']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
299	roche	RG6078+atezolizumab	['Oncology']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
300	roche	RG6078	['A', 'cancer']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
301	roche	ACE910	[]	3	['antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
302	roche	RG6168	['A', 'neuromyelitis']	3	['monoclonal', 'antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
303	roche	RG7413	['ulcerative']	3	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
304	roche	RG7413	['disease', 'bowel']	3	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
305	roche	immunocytokine	['A']	1	['antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
306	roche	immunocytokine	['A']	1	['cytokine', 'antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
307	roche	immunocytokine	['tumors']	1	['cytokine', 'antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
308	roche	RG7461	['Oncology', 'tumours']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
309	roche	RG7461	['tumours']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
310	roche	RG7461	['A', 'tumours']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
311	roche	RG1569	['sclerosis']	3	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
312	roche	RG1569	[]	3	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
313	roche	RG1569	['rheumatoid', 'arthritis', 'vasculitis']	3	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
314	roche	RG7861	['aureus', 'Diseases', 'Staphylococcus']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
315	roche	RG7861	['aureus', 'Staphylococcus', 'conjugate']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
316	roche	RG7854	['B', 'hepatitis', 'infection', 'Diseases']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
317	roche	RG7854	['B', 'hepatitis', 'infection']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
318	roche	Lebrikizumab	['A', 'fibrosis', 'idiopathic', 'pulmonary']	2	['monoclonal', 'antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
319	roche	Lebrikizumab	['inflammatory', 'dermatitis']	2	['monoclonal', 'antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
320	roche	Lebrikizumab	['A', 'disease', 'chronic', 'pulmonary']	2	['monoclonal', 'antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
321	roche	RG6146	['Oncology']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
322	roche	RG6146	['Oncology']	1	['inhibitor']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
323	roche	RG6146	['cancer']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
324	roche	Lampalizumab	['atrophy', 'chronic']	3	['monoclonal', 'antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
325	roche	gantenerumab	"['disease', ""Alzheimer's""]"	3	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
326	roche	RG6016	['Oncology', 'tumors']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
327	roche	RG6016	['tumors']	1	['inhibitor']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
328	roche	RG7604	['breast', 'Oncology']	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
329	roche	RG7604	['breast', 'Oncology', 'cancer']	3	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
330	roche	RG7604	['breast', 'cancer']	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
331	roche	T-DM1	[]	3	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
332	roche	Ocrelizumab	['disease', 'sclerosis', 'inflammatory']	1	['monoclonal', 'antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
333	roche	RG7990	['asthma']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
334	roche	RG7412	"['disease', ""Alzheimer's""]"	3	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
335	roche	RG7935	"[""Parkinson's"", 'disease']"	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
336	roche	RG7935	"[""Parkinson's"", 'disease']"	1	['monoclonal', 'antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
337	roche	RG6013	['hemophilia']	3	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
338	roche	RG6013	['atrophy', 'hemophilia']	3	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
339	roche	trastuzumab	['breast', 'Oncology']	2	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
340	roche	trastuzumab	['conjugate']	1	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
341	roche	trastuzumab	['breast', 'Oncology']	3	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
342	roche	RG7916	['atrophy']	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
343	roche	RG7916	['hepatitis', 'atrophy', 'B', 'infection']	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
344	roche	ERY974	[]	1	['antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
345	roche	crenezumab	"['disease', ""Alzheimer's""]"	3	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
346	roche	RG1594	['sclerosis']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
347	roche	RG7741	['tumor', 'Oncology', 'lymphoma', 'tumors']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
348	roche	RG7741	['tumor']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
349	roche	cobimetinib	['Oncology']	1	['tyrosine-kinase inhibitor']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
350	roche	cobimetinib	['Oncology', 'tumours']	1	['tyrosine-kinase inhibitor']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
351	roche	cobimetinib	['Cancer']	1	['tyrosine-kinase inhibitor']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
352	roche	cobimetinib	['breast', 'Oncology', 'cancer']	2	['tyrosine-kinase inhibitor']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
353	roche	cobimetinib+atezolizumab	['Oncology']	3	['tyrosine-kinase inhibitor']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
354	roche	cobimetinib+atezolizumab	['Oncology']	1	['tyrosine-kinase inhibitor']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
355	roche	RG3502	['Oncology']	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
356	roche	RG3502	['Oncology']	3	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
357	roche	RG3502	['cancer']	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
358	roche	emicizumab	['hemophilia']	3	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
359	roche	VISION4	[]	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
360	roche	Anti-OX40	[]	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
361	roche	RG7203	['schizophrenia']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
362	roche	RG7203	['schizophrenia']	1	['inhibitor']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
363	roche	RG7203	[]	1	['inhibitor']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
364	roche	RG7853	['Oncology']	3	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
365	roche	vanucizumab	['tumours']	1	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
366	roche	vanucizumab	[]	1	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
367	roche	vanucizumab	['cancer']	2	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
368	roche		['Oncology']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
369	roche	RG7227	['Diseases']	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
370	roche	MOXR0916	[]	False	['monoclonal']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
371	roche	RG7906	['disorders', 'psychiatric']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
372	roche	RG6058	['Oncology', 'tumours']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
373	roche	RG6058	['tumours']	1	['monoclonal', 'antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
374	roche	ARN-927	['breast', 'cancer']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
375	roche	HIF-1	['disease']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
376	roche	URC102	['gout']	2	['inhibitor']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
377	roche	URC102	['A']	3	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
378	roche	URC102	['A']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
379	roche	Frontline	['chronic', 'lymphocytic']	3	['chemical substance']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
380	roche	RG6152	['Diseases', 'influenza']	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
381	roche	RG6152	['A', 'B', 'seasonal', 'influenza']	2	['inhibitor']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
382	roche	RG6152	['A', 'seasonal', 'Japanese', 'influenza', 'B']	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
383	roche	RG1450	"['disease', ""Alzheimer's""]"	3	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
384	roche	RG1273	['Oncology']	3	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
385	roche	RG7686	['Oncology']	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
386	roche	RG7686	['liver', 'cancer']	2	['monoclonal', 'antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
387	roche	RG6125	['rheumatoid', 'inflammatory', 'arthritis']	2	['monoclonal', 'antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
388	roche	RG6125	['rheumatoid', 'arthritis', 'vasculitis']	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
389	roche	Emicizumab	['congenital', 'hemophilia']	3	['antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
390	roche	PCO371	[]	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
391	roche	RG7876	['Cancer', 'Oncology', 'tumors']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
392	roche	RG7876	['tumors']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
393	roche	RG7876+atezolizumab	['Oncology']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
394	roche	RG7876	['tumor', 'tumors']	1	['antibody', 'antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
395	roche	RG7876+vanucizumab	['Oncology']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
396	roche	RG7876	['tumor', 'tumours']	1	['antibody', 'antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
397	roche	Etrolizumab	['ulcerative']	3	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
398	roche	Etrolizumab	['disease']	3	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
399	roche	RG6080	['Diseases']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
400	roche	RG6080	['Diseases']	1	['inhibitor']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
401	roche	RG6080	[]	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
402	roche	Nemolizumab	['dermatitis']	2	['monoclonal', 'antibody', 'interleukin-31']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
403	roche	Nemolizumab	[]	2	['monoclonal', 'antibody', 'interleukin-31']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
404	roche		['Cancer', 'Oncology', 'tumors']	1	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
405	roche	atezolizumab	['Cancer', 'tumors']	1	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
406	roche	atezolizumab	['tumors']	1	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
407	roche	atezolizumab	['A', 'Cancer', 'cancer', 'prostate']	1	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
408	roche	atezolizumab	['A', 'Cancer', 'myelodysplastic', 'cancer']	1	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
409	roche	atezolizumab	['A', 'Cancer', 'cancer']	1	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
410	roche	atezolizumab	['Cancer', 'breast', 'cancer']	1	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
411	roche	atezolizumab	['A', 'cancer']	1	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
412	roche	atezolizumab	['A', 'cancer', 'tumours']	1	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
413	roche	atezolizumab+obinutuzumab	['Cancer', 'Oncology', 'lymphoma']	1	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
414	roche	atezolizumab	['A', 'B', 'cancer', 'lymphoma']	1	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
415	roche	atezolizumab+erlotinib	['Oncology']	1	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
416	roche	atezolizumab	['Cancer']	1	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
417	roche	atezolizumab	['A', 'Oncology', 'cancer']	1	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
418	roche	atezolizumab	['Cancer', 'Oncology', 'tumors']	1	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
419	roche	atezolizumab	['A', 'cancer', 'Oncology', 'tumours']	1	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
420	roche	atezolizumab	['Oncology']	1	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
421	roche	atezolizumab	['tumors']	1	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
422	roche	atezolizumab	['tumours']	1	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
423	roche	atezolizumab	['A', 'cancer']	3	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
424	roche	atezolizumab	['Cancer', 'cancer']	3	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
425	roche	atezolizumab	['Cancer', 'cancer', 'prostate']	3	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
426	roche	atezolizumab	['A', 'Cancer', 'cancer']	3	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
427	roche	atezolizumab	['Cancer']	3	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
428	roche	atezolizumab	['Cancer', 'breast']	3	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
429	roche	atezolizumab	['Cancer', 'Oncology', 'cancer']	3	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
430	roche	atezolizumab	['Cancer', 'cancer']	1	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
431	roche	atezolizumab	[]	1	['PD-L1', 'PD-L1']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
432	roche	atezolizumab	['Diabetes']	1	['PD-L1']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
433	roche	RG7601	['tumor', 'chronic', 'lymphocytic', 'Oncology']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
434	roche	RG7601	['chronic', 'lymphocytic', 'Oncology']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
435	roche	RG7601	['chronic', 'tumor', 'lymphocytic']	1	['Bcl-2', 'inhibitor']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
436	roche	RG7601	['A', 'tumor', 'Oncology']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
437	roche	RG7601	['B', 'tumor', 'Oncology', 'lymphoma']	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
438	roche	RG7601	['Oncology', 'lymphoma']	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
439	roche	RG7601	['A', 'tumor', 'lymphoma']	2	['Bcl-2', 'inhibitor']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
440	roche	RG7601	['A', 'lymphoma']	2	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
441	roche	RG7601	['Oncology']	3	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
442	roche	RG7601	['chronic', 'tumor', 'lymphocytic']	3	['Bcl-2', 'inhibitor']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
443	roche	RG7601	['tumor', 'Oncology']	3	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
444	roche	RG7601	['chronic', 'lymphocytic', 'Oncology']	3	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
445	roche	RG7601	['A', 'tumor', 'lymphocytic', 'chronic']	3	['Bcl-2', 'inhibitor']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
446	roche	RG7601	['A', 'chronic', 'lymphocytic']	3	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
447	roche	rituximab	['chronic', 'lymphocytic']	2	['Chimeric antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
448	roche	rituximab	[]	3	['monoclonal', 'antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
449	roche	NLG919	[]	False	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
450	roche	RG6029	[]	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
451	roche	RG6029	['peripheral']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
452	roche	ABT-199	[]	3	['Bcl-2', 'inhibitor']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
453	roche	RG6185	['Oncology']	1	['inhibitor']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
454	roche	RG6185	['breast', 'hemophilia']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
455	roche	Pertuzumab	['cancer']	3	['monoclonal', 'antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
456	roche	Pertuzumab	['breast', 'cancer']	3	['monoclonal', 'antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
457	roche	Pertuzumab	[]	3	['monoclonal', 'antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
458	roche	RG6180	['Oncology']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
459	roche	RG6180	['breast', 'cancer']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
460	roche	RG6047	['breast', 'Oncology', 'cancer']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
461	roche	RG6047	['breast', 'cancer']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
462	roche	Crenezumab	"['disease', ""Alzheimer's""]"	3	['monoclonal']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
463	roche	GA101	['lupus']	2	['monoclonal']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
464	roche	Ranibizumab	[]	2	['monoclonal', 'antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
465	roche	MDM2-p53	[]	3	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
466	roche	Obinutuzumab	['lupus']	2	['monoclonal']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
467	roche	azacitidine	['A', 'myelodysplastic']	1	[]	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
468	roche	pertuzumab	['cancer']	3	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
469	roche	pertuzumab	['cancer']	1	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
470	roche	pertuzumab	[]	1	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
471	roche	pertuzumab	['breast', 'cancer']	3	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
472	roche	pertuzumab	['breast']	3	['humanized antibody']	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm	[]
473	acorda therapeutics, inc.	CVT-427	['disease', 'acute']	False	[]	http://www.acorda.com/products/pipeline	[]
474	acorda therapeutics, inc.	CVT-427	"[""Parkinson's"", 'Migraine', 'Disease']"	False	[]	http://www.acorda.com/products/pipeline	[]
475	acorda therapeutics, inc.	SYN120	['disease']	False	[]	http://www.acorda.com/products/pipeline	[]
476	acorda therapeutics, inc.	SYN120	"[""Parkinson's"", 'Disease']"	1	[]	http://www.acorda.com/products/pipeline	[]
477	acorda therapeutics, inc.	CVT-301	['disease']	False	[]	http://www.acorda.com/products/pipeline	[]
478	acorda therapeutics, inc.	CVT-301	"[""Parkinson's"", 'Disease']"	1	[]	http://www.acorda.com/products/pipeline	[]
479	acorda therapeutics, inc.	BTT1023	"[""Parkinson's"", 'Disease']"	1	[]	http://www.acorda.com/products/pipeline	[]
480	astrazeneca pharmaceuticals lp	tremelimumab	['tumours']	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
481	astrazeneca pharmaceuticals lp	tremelimumab	['tumours']	1	['PD-L1', 'mAb']	https://www.astrazeneca.com/our-science/pipeline.html	[]
482	astrazeneca pharmaceuticals lp	tremelimumab+MEDI0562	['tumours']	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
483	astrazeneca pharmaceuticals lp	tremelimumab	[]	2	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
484	astrazeneca pharmaceuticals lp	tremelimumab	[]	2	['PD-L1', 'mAb']	https://www.astrazeneca.com/our-science/pipeline.html	[]
485	astrazeneca pharmaceuticals lp	tremelimumab	['cancer']	2	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
486	astrazeneca pharmaceuticals lp	tremelimumab	['cancer']	2	['PD-L1', 'mAb']	https://www.astrazeneca.com/our-science/pipeline.html	[]
487	astrazeneca pharmaceuticals lp	tremelimumab	[]	3	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
488	astrazeneca pharmaceuticals lp	tremelimumab	[]	3	['PD-L1', 'mAb']	https://www.astrazeneca.com/our-science/pipeline.html	[]
489	astrazeneca pharmaceuticals lp	tremelimumab	[]	1	['mAb']	https://www.astrazeneca.com/our-science/pipeline.html	[]
490	astrazeneca pharmaceuticals lp	tremelimumab	[]	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
491	astrazeneca pharmaceuticals lp	selumetinib	['tumours']	1	['tyrosine-kinase inhibitor']	https://www.astrazeneca.com/our-science/pipeline.html	[]
492	astrazeneca pharmaceuticals lp	selumetinib	['tumours']	1	['PD-L1', 'MEK', 'inhibitor']	https://www.astrazeneca.com/our-science/pipeline.html	[]
493	astrazeneca pharmaceuticals lp	selumetinib	[]	1	['tyrosine-kinase inhibitor']	https://www.astrazeneca.com/our-science/pipeline.html	[]
494	astrazeneca pharmaceuticals lp	selumetinib	[]	2	['tyrosine-kinase inhibitor']	https://www.astrazeneca.com/our-science/pipeline.html	[]
495	astrazeneca pharmaceuticals lp	selumetinib	['cancer']	3	['tyrosine-kinase inhibitor']	https://www.astrazeneca.com/our-science/pipeline.html	[]
496	astrazeneca pharmaceuticals lp	selumetinib	['breast', 'cancer', 'prostate']	3	['MEK', 'inhibitor']	https://www.astrazeneca.com/our-science/pipeline.html	[]
497	astrazeneca pharmaceuticals lp	AZD5718	[]	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
498	astrazeneca pharmaceuticals lp	AZD5718	[]	1	['FLAP']	https://www.astrazeneca.com/our-science/pipeline.html	[]
499	astrazeneca pharmaceuticals lp	acalabrutinib	[]	3	['tyrosine-kinase inhibitor']	https://www.astrazeneca.com/our-science/pipeline.html	[]
500	astrazeneca pharmaceuticals lp	acalabrutinib	[]	3	['inhibitor']	https://www.astrazeneca.com/our-science/pipeline.html	[]
501	astrazeneca pharmaceuticals lp	MEDI4166	[]	2	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
502	astrazeneca pharmaceuticals lp	AZD4547	['tumours']	2	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
503	astrazeneca pharmaceuticals lp	MEDI7734	[]	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
504	astrazeneca pharmaceuticals lp	AZD8186	['tumours']	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
505	astrazeneca pharmaceuticals lp	mavrilimumab	['rheumatoid']	2	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
506	astrazeneca pharmaceuticals lp	mavrilimumab	['rheumatoid', 'gout', 'arthritis', 'chronic']	2	['mAb']	https://www.astrazeneca.com/our-science/pipeline.html	[]
507	astrazeneca pharmaceuticals lp	MEDI2070	['Crohn’s']	False	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
508	astrazeneca pharmaceuticals lp	MEDI2070	['disease', 'MRSA', 'Crohn’s']	False	['mAb']	https://www.astrazeneca.com/our-science/pipeline.html	[]
509	astrazeneca pharmaceuticals lp	AZD4635	['tumours']	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
510	astrazeneca pharmaceuticals lp	AZD4635	['tumours']	1	['inhibitor']	https://www.astrazeneca.com/our-science/pipeline.html	[]
511	astrazeneca pharmaceuticals lp	AZD8108	[]	False	['inhibitor']	https://www.astrazeneca.com/our-science/pipeline.html	[]
512	astrazeneca pharmaceuticals lp	AZD8108	[]	False	['antagonist']	https://www.astrazeneca.com/our-science/pipeline.html	[]
513	astrazeneca pharmaceuticals lp	AZD4831	['Diseases']	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
514	astrazeneca pharmaceuticals lp	AZD4831	[]	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
515	astrazeneca pharmaceuticals lp	MEDI0382	[]	2	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
516	astrazeneca pharmaceuticals lp	MEDI8897	['RSV']	2	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
517	astrazeneca pharmaceuticals lp	AZD7986	['COPD']	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
518	astrazeneca pharmaceuticals lp	STAT3	[]	1	['inhibitor']	https://www.astrazeneca.com/our-science/pipeline.html	[]
519	astrazeneca pharmaceuticals lp	STAT3	['lymphoma']	1	['inhibitor)', 'mAb', 'PD-L1', 'mAb', 'PD-L1']	https://www.astrazeneca.com/our-science/pipeline.html	[]
520	astrazeneca pharmaceuticals lp	STAT3	[]	2	['inhibitor', 'mAb', 'PD-L1']	https://www.astrazeneca.com/our-science/pipeline.html	[]
521	astrazeneca pharmaceuticals lp	CTLA-4	['tumours']	1	['mAb', 'mAb', 'PD-L1']	https://www.astrazeneca.com/our-science/pipeline.html	[]
522	astrazeneca pharmaceuticals lp	CTLA-4	['tumours']	1	['mAb']	https://www.astrazeneca.com/our-science/pipeline.html	[]
523	astrazeneca pharmaceuticals lp	CTLA-4	[]	2	['mAb', 'mAb', 'PD-L1']	https://www.astrazeneca.com/our-science/pipeline.html	[]
524	astrazeneca pharmaceuticals lp	CTLA-4	['cancer']	2	['mAb', 'mAb', 'PD-L1']	https://www.astrazeneca.com/our-science/pipeline.html	[]
525	astrazeneca pharmaceuticals lp	CTLA-4	[]	3	['mAb', 'mAb', 'PD-L1']	https://www.astrazeneca.com/our-science/pipeline.html	[]
526	astrazeneca pharmaceuticals lp	CTLA-4	[]	1	['mAb', 'mAb']	https://www.astrazeneca.com/our-science/pipeline.html	[]
527	astrazeneca pharmaceuticals lp	savolitinib	[]	2	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
528	astrazeneca pharmaceuticals lp	benralizumab	['asthma']	3	['humanized antibody']	https://www.astrazeneca.com/our-science/pipeline.html	[]
529	astrazeneca pharmaceuticals lp	benralizumab	['asthma']	3	['mAb']	https://www.astrazeneca.com/our-science/pipeline.html	[]
530	astrazeneca pharmaceuticals lp	benralizumab	['COPD']	3	['humanized antibody']	https://www.astrazeneca.com/our-science/pipeline.html	[]
531	astrazeneca pharmaceuticals lp	benralizumab	['COPD']	3	['mAb']	https://www.astrazeneca.com/our-science/pipeline.html	[]
532	astrazeneca pharmaceuticals lp	MEDI4920	['syndrome']	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
533	astrazeneca pharmaceuticals lp	inebilizumab	['neuromyelitis']	2	['humanized antibody']	https://www.astrazeneca.com/our-science/pipeline.html	[]
534	astrazeneca pharmaceuticals lp	inebilizumab	['sclerosis', 'Neuromyelitis', 'neuromyelitis']	2	['CD19', 'mAb']	https://www.astrazeneca.com/our-science/pipeline.html	[]
535	astrazeneca pharmaceuticals lp	AZD7594	[]	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
536	astrazeneca pharmaceuticals lp	AZD7594	[]	2	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
537	astrazeneca pharmaceuticals lp	MEDI9314	['dermatitis']	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
538	astrazeneca pharmaceuticals lp	MEDI9314	['dermatitis']	1	['mAb']	https://www.astrazeneca.com/our-science/pipeline.html	[]
539	astrazeneca pharmaceuticals lp	MEDI0680	['tumours']	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
540	astrazeneca pharmaceuticals lp	MEDI0680	['tumours']	2	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
541	astrazeneca pharmaceuticals lp	MEDI0680	['tumours']	2	['PD-L1', 'mAb']	https://www.astrazeneca.com/our-science/pipeline.html	[]
542	astrazeneca pharmaceuticals lp	MEDI9197	['tumours']	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
543	astrazeneca pharmaceuticals lp	MEDI4893	['aureus']	2	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
544	astrazeneca pharmaceuticals lp	MEDI4893	['aureus', 'infection']	2	['mAb']	https://www.astrazeneca.com/our-science/pipeline.html	[]
545	astrazeneca pharmaceuticals lp	linaclotide	['syndrome', 'bowel', 'constipation']	False	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
546	astrazeneca pharmaceuticals lp	MEDI5872	['syndrome']	2	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
547	astrazeneca pharmaceuticals lp	MEDI5872	['syndrome']	2	['B7RP1', 'mAb']	https://www.astrazeneca.com/our-science/pipeline.html	[]
548	astrazeneca pharmaceuticals lp	MEDI0700	['lupus']	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
549	astrazeneca pharmaceuticals lp	MEDI6012	[]	2	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
550	astrazeneca pharmaceuticals lp	MEDI6012	['thrombosis', 'arterial']	2	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
551	astrazeneca pharmaceuticals lp	MEDI1873	['tumours']	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
552	astrazeneca pharmaceuticals lp	MEDI8111	[]	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
553	astrazeneca pharmaceuticals lp	MEDI0562	['tumours']	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
554	astrazeneca pharmaceuticals lp	MEDI0562	['tumours']	1	['PD-L1', 'mAb']	https://www.astrazeneca.com/our-science/pipeline.html	[]
555	astrazeneca pharmaceuticals lp	tralokinumab	['asthma']	3	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
556	astrazeneca pharmaceuticals lp	MEDI7352	['osteoarthritis']	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
557	astrazeneca pharmaceuticals lp	MEDI7352	['osteoarthritis']	1	['mAb']	https://www.astrazeneca.com/our-science/pipeline.html	[]
558	astrazeneca pharmaceuticals lp	AZD5363	['breast']	2	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
559	astrazeneca pharmaceuticals lp	AZD5363	['breast', 'cancer']	2	['inhibitor']	https://www.astrazeneca.com/our-science/pipeline.html	[]
560	astrazeneca pharmaceuticals lp	AZD9150	[]	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
561	astrazeneca pharmaceuticals lp	AZD9150	[]	2	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
562	astrazeneca pharmaceuticals lp	AZD9150	[]	2	['PD-L1', 'mAb']	https://www.astrazeneca.com/our-science/pipeline.html	[]
563	astrazeneca pharmaceuticals lp	MEDI4276	['tumours']	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
564	astrazeneca pharmaceuticals lp	CXCR2	[]	2	['PD-L1', 'mAb', 'mAb', 'PD-L1']	https://www.astrazeneca.com/our-science/pipeline.html	[]
565	astrazeneca pharmaceuticals lp	MEDI-565	['tumours']	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
566	astrazeneca pharmaceuticals lp	MEDI-565	['tumours']	1	['mAb']	https://www.astrazeneca.com/our-science/pipeline.html	[]
567	astrazeneca pharmaceuticals lp	PT010	['asthma']	2	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
568	astrazeneca pharmaceuticals lp	PT010	['COPD']	3	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
569	astrazeneca pharmaceuticals lp	MEDI9447	['tumours']	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
570	astrazeneca pharmaceuticals lp	MEDI9447	['tumours']	1	['PD-L1', 'mAb']	https://www.astrazeneca.com/our-science/pipeline.html	[]
571	astrazeneca pharmaceuticals lp	AZD3293	"[""Alzheimer's""]"	3	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
572	astrazeneca pharmaceuticals lp	AZD3293	"['disease', ""Alzheimer's""]"	3	['inhibitor']	https://www.astrazeneca.com/our-science/pipeline.html	[]
573	astrazeneca pharmaceuticals lp	MEDI-573	['breast']	2	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
574	astrazeneca pharmaceuticals lp	MEDI-573	['breast', 'cancer']	2	['mAb']	https://www.astrazeneca.com/our-science/pipeline.html	[]
575	astrazeneca pharmaceuticals lp	AZD6738	['tumours']	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
576	astrazeneca pharmaceuticals lp	AZD6738	['cancer']	2	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
577	astrazeneca pharmaceuticals lp	AZD6738	['cancer']	2	['inhibitor', 'inhibitor']	https://www.astrazeneca.com/our-science/pipeline.html	[]
578	astrazeneca pharmaceuticals lp	monalizumab	['tumours']	1	['humanized antibody']	https://www.astrazeneca.com/our-science/pipeline.html	[]
579	astrazeneca pharmaceuticals lp	monalizumab	['tumours']	1	['PD-L1', 'mAb', 'mAb']	https://www.astrazeneca.com/our-science/pipeline.html	[]
580	astrazeneca pharmaceuticals lp	MEDI1814	['disease']	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
581	astrazeneca pharmaceuticals lp	MEDI1814	['disease']	1	['mAb']	https://www.astrazeneca.com/our-science/pipeline.html	[]
582	astrazeneca pharmaceuticals lp	MEDI3902	['pneumonia']	2	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
583	astrazeneca pharmaceuticals lp	MEDI3902	['pneumonia']	2	['mAb']	https://www.astrazeneca.com/our-science/pipeline.html	[]
584	astrazeneca pharmaceuticals lp	AZD0156	['Oncology', 'tumours']	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
585	astrazeneca pharmaceuticals lp	AZD0156	['tumours']	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
586	astrazeneca pharmaceuticals lp	AZD5634	['fibrosis']	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
587	astrazeneca pharmaceuticals lp	MEDI7510	['disease', 'RSV']	False	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
588	astrazeneca pharmaceuticals lp	AZD1419	['asthma']	2	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
589	astrazeneca pharmaceuticals lp	SGLT-2	['diabetes']	3	['inhibitor']	https://www.astrazeneca.com/our-science/pipeline.html	[]
590	astrazeneca pharmaceuticals lp	SGLT-2	['diabetes']	2	['inhibitor']	https://www.astrazeneca.com/our-science/pipeline.html	[]
591	astrazeneca pharmaceuticals lp	DPP-4	['diabetes']	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
592	astrazeneca pharmaceuticals lp	DPP-4	['diabetes']	2	['inhibitor']	https://www.astrazeneca.com/our-science/pipeline.html	[]
593	astrazeneca pharmaceuticals lp	DPP-4	['diabetes']	2	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
594	astrazeneca pharmaceuticals lp	moxetumomab	[]	3	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
595	astrazeneca pharmaceuticals lp	AZD0284	['Respiratory', 'psoriasis']	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
596	astrazeneca pharmaceuticals lp	AZD0284	['psoriasis']	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
597	astrazeneca pharmaceuticals lp	AZD1775	['tumours']	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
598	astrazeneca pharmaceuticals lp	AZD1775	['tumours']	1	['inhibitor']	https://www.astrazeneca.com/our-science/pipeline.html	[]
599	astrazeneca pharmaceuticals lp	AZD1775	['tumours']	2	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
600	astrazeneca pharmaceuticals lp	AZD1775	['ovarian']	2	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
601	astrazeneca pharmaceuticals lp	AZD1775	['ovarian', 'cancer']	2	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
602	astrazeneca pharmaceuticals lp	AZD5069	[]	2	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
603	astrazeneca pharmaceuticals lp	MEDI8852	['A', 'influenza']	2	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
604	astrazeneca pharmaceuticals lp	MEDI8852	['A', 'influenza']	2	['mAb']	https://www.astrazeneca.com/our-science/pipeline.html	[]
605	astrazeneca pharmaceuticals lp	tezepelumab	['dermatitis']	2	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
606	astrazeneca pharmaceuticals lp	tezepelumab	['COPD', 'dermatitis']	2	['mAb']	https://www.astrazeneca.com/our-science/pipeline.html	[]
607	astrazeneca pharmaceuticals lp	AZD8601	[]	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
608	astrazeneca pharmaceuticals lp	AZD2811	['B', 'tumours']	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
609	astrazeneca pharmaceuticals lp	AZD2811	['B', 'tumours']	1	['inhibitor']	https://www.astrazeneca.com/our-science/pipeline.html	[]
610	astrazeneca pharmaceuticals lp	volitinib	[]	2	['tyrosine-kinase inhibitor']	https://www.astrazeneca.com/our-science/pipeline.html	[]
611	astrazeneca pharmaceuticals lp	AURA3	[]	3	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
612	astrazeneca pharmaceuticals lp	durvalumab+AZD1775	['tumours']	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
613	astrazeneca pharmaceuticals lp	durvalumab	[]	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
614	astrazeneca pharmaceuticals lp	durvalumab	[]	1	['PD-L1']	https://www.astrazeneca.com/our-science/pipeline.html	[]
615	astrazeneca pharmaceuticals lp	durvalumab+MEDI0562	['tumours']	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
616	astrazeneca pharmaceuticals lp	durvalumab+MEDI9447	['tumours']	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
617	astrazeneca pharmaceuticals lp	durvalumab+monalizumab	['tumours']	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
618	astrazeneca pharmaceuticals lp	durvalumab+selumetinib	['tumours']	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
619	astrazeneca pharmaceuticals lp	durvalumab+tremelimumab	['tumours']	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
620	astrazeneca pharmaceuticals lp	durvalumab	['lymphoma']	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
621	astrazeneca pharmaceuticals lp	durvalumab	['lymphoma']	1	['PD-L1', 'mAb', 'PD-L1']	https://www.astrazeneca.com/our-science/pipeline.html	[]
622	astrazeneca pharmaceuticals lp	durvalumab	['tumours']	2	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
623	astrazeneca pharmaceuticals lp	durvalumab	['tumours']	2	['PD-L1', 'mAb']	https://www.astrazeneca.com/our-science/pipeline.html	[]
624	astrazeneca pharmaceuticals lp	durvalumab+AZD5069	[]	2	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
625	astrazeneca pharmaceuticals lp	durvalumab+AZD9150	[]	2	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
626	astrazeneca pharmaceuticals lp	durvalumab+MEDI0680	['tumours']	2	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
627	astrazeneca pharmaceuticals lp	durvalumab+tremelimumab	[]	2	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
628	astrazeneca pharmaceuticals lp	durvalumab+tremelimumab	['cancer']	2	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
629	astrazeneca pharmaceuticals lp	durvalumab	['cancer']	3	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
630	astrazeneca pharmaceuticals lp	durvalumab	['cancer']	3	['PD-L1', 'mAb']	https://www.astrazeneca.com/our-science/pipeline.html	[]
631	astrazeneca pharmaceuticals lp	durvalumab	[]	3	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
632	astrazeneca pharmaceuticals lp	durvalumab	[]	3	['PD-L1', 'mAb']	https://www.astrazeneca.com/our-science/pipeline.html	[]
633	astrazeneca pharmaceuticals lp	durvalumab+tremelimumab	[]	3	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
634	astrazeneca pharmaceuticals lp	durvalumab	['tumours']	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
635	astrazeneca pharmaceuticals lp	durvalumab	['tumours']	1	['mAb']	https://www.astrazeneca.com/our-science/pipeline.html	[]
636	astrazeneca pharmaceuticals lp	durvalumab+tremelimumab	['tumours']	1	['mAb']	https://www.astrazeneca.com/our-science/pipeline.html	[]
637	astrazeneca pharmaceuticals lp	durvalumab+tremelimumab	[]	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
638	astrazeneca pharmaceuticals lp	durvalumab+tremelimumab	[]	1	['mAb']	https://www.astrazeneca.com/our-science/pipeline.html	[]
639	astrazeneca pharmaceuticals lp	durvalumab	['pneumonia']	1	['inhibitor']	https://www.astrazeneca.com/our-science/pipeline.html	[]
640	astrazeneca pharmaceuticals lp	GLP-1	['diabetes']	2	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
641	astrazeneca pharmaceuticals lp	GLP-1	['diabetes']	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
642	astrazeneca pharmaceuticals lp	SGLT2	['diabetes']	2	['inhibitor']	https://www.astrazeneca.com/our-science/pipeline.html	[]
643	astrazeneca pharmaceuticals lp	SGLT2	['diabetes', 'Respiratory']	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
644	astrazeneca pharmaceuticals lp	AZD9567	['rheumatoid']	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
645	astrazeneca pharmaceuticals lp	AZD9567	['rheumatoid', 'arthritis']	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
646	astrazeneca pharmaceuticals lp	AZD9412	[]	2	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
647	astrazeneca pharmaceuticals lp	investigationprostate	[]	Unknown	False	https://www.astrazeneca.com/our-science/pipeline.html	[]
648	astrazeneca pharmaceuticals lp	P2Y12	['diabetes', 'thrombosis', 'arterial']	3	['antagonist']	https://www.astrazeneca.com/our-science/pipeline.html	[]
649	astrazeneca pharmaceuticals lp	P2Y12	['sickle', 'disease']	3	['antagonist']	https://www.astrazeneca.com/our-science/pipeline.html	[]
650	astrazeneca pharmaceuticals lp	P2Y12	['sickle', 'stroke', 'disease', 'diabetes']	3	['antagonist']	https://www.astrazeneca.com/our-science/pipeline.html	[]
651	astrazeneca pharmaceuticals lp	P2Y12	['stroke', 'diabetes']	3	['antagonist']	https://www.astrazeneca.com/our-science/pipeline.html	[]
652	astrazeneca pharmaceuticals lp	AZD8871	['COPD']	2	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
653	astrazeneca pharmaceuticals lp	AZD3241	['atrophy']	2	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
654	astrazeneca pharmaceuticals lp	AZD3241	['atrophy']	2	['inhibitor']	https://www.astrazeneca.com/our-science/pipeline.html	[]
655	astrazeneca pharmaceuticals lp	anifrolumab	['lupus']	3	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
656	astrazeneca pharmaceuticals lp	anifrolumab	['lupus']	1	['mAb']	https://www.astrazeneca.com/our-science/pipeline.html	[]
657	astrazeneca pharmaceuticals lp	anifrolumab	['lupus']	2	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
658	astrazeneca pharmaceuticals lp	anifrolumab	['lupus']	2	['mAb']	https://www.astrazeneca.com/our-science/pipeline.html	[]
659	astrazeneca pharmaceuticals lp	anifrolumab	['lupus']	3	['mAb']	https://www.astrazeneca.com/our-science/pipeline.html	[]
660	astrazeneca pharmaceuticals lp	trametinib	[]	1	['tyrosine-kinase inhibitor']	https://www.astrazeneca.com/our-science/pipeline.html	[]
661	astrazeneca pharmaceuticals lp	trametinib	[]	1	['PD-L1', 'inhibitor', 'MEK', 'inhibitor']	https://www.astrazeneca.com/our-science/pipeline.html	[]
662	astrazeneca pharmaceuticals lp	IL-13	['asthma', 'COPD']	3	['mAb']	https://www.astrazeneca.com/our-science/pipeline.html	[]
663	astrazeneca pharmaceuticals lp	AZD9496	['breast']	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
664	astrazeneca pharmaceuticals lp	AZD9496	['breast', 'cancer']	1	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
665	astrazeneca pharmaceuticals lp	AZD4076	['liver']	2	[]	https://www.astrazeneca.com/our-science/pipeline.html	[]
666	astrazeneca pharmaceuticals lp	AZD4076	['liver']	2	['oligonucleotide']	https://www.astrazeneca.com/our-science/pipeline.html	[]
667	avanir pharmaceuticals, inc.	AVP-825	['Migraine', 'Acute']	1	[]	http://www.avanir.com/science/pipeline	[]
668	avanir pharmaceuticals, inc.	AVP-825	['acute']	3	[]	http://www.avanir.com/science/pipeline	[]
669	avanir pharmaceuticals, inc.	Phone+1.949.643.6800	[]	False	[]	http://www.avanir.com/science/pipeline	[]
670	avanir pharmaceuticals, inc.	AVP-923	['Sclerosis', 'Amyotrophic']	1	[]	http://www.avanir.com/science/pipeline	[]
671	avanir pharmaceuticals, inc.	AVP-923	[]	3	[]	http://www.avanir.com/science/pipeline	[]
672	avanir pharmaceuticals, inc.	AVP-786	['disease']	1	[]	http://www.avanir.com/science/pipeline	[]
673	avanir pharmaceuticals, inc.	AVP-786	['Schizophrenia']	3	[]	http://www.avanir.com/science/pipeline	[]
674	avanir pharmaceuticals, inc.	AVP-786	['schizophrenia']	3	[]	http://www.avanir.com/science/pipeline	[]
675	avanir pharmaceuticals, inc.	AVP-786	['Disorders', 'Brain']	3	[]	http://www.avanir.com/science/pipeline	[]
676	avanir pharmaceuticals, inc.	AVP-786	['A', 'brain', 'common']	3	[]	http://www.avanir.com/science/pipeline	[]
677	chugai-pharm	bevacizumab	['Malignant']	3	['monoclonal', 'antibody']	/english/ir/pdf/170425ePipeline.pdf	['PDF link provided']
678	chugai-pharm	alectinib	['cancer']	False	['inhibitor']	/english/ir/pdf/170425ePipeline.pdf	['PDF link provided']
679	chugai-pharm	RG7446	[]	False	['antibody', 'monoclonal']	/english/ir/pdf/170425ePipeline.pdf	['PDF link provided']
680	chugai-pharm	RG3637	['fibrosis', 'A', 'Hemophilia', 'pulmonary', 'Idiopathic']	3	['antibody']	/english/ir/pdf/170425ePipeline.pdf	['PDF link provided']
681	chugai-pharm	URC102	['Gout']	2	[]	/english/ir/pdf/170425ePipeline.pdf	['PDF link provided']
682	chugai-pharm	RG1450	['disease']	3	[]	/english/ir/pdf/170425ePipeline.pdf	['PDF link provided']
683	chugai-pharm	CKI27	['tumors']	1	['MEK', 'inhibitor', 'antibody', 'monoclonal', 'Anti-Glypican-3']	/english/ir/pdf/170425ePipeline.pdf	['PDF link provided']
684	chugai-pharm	RG1273	['Breast', 'cancer', 'Malignant']	3	['antibody', 'monoclonal']	/english/ir/pdf/170425ePipeline.pdf	['PDF link provided']
685	chugai-pharm	polatuzumab	['tumors', 'conjugate']	1	['humanized antibody']	/english/ir/pdf/170425ePipeline.pdf	['PDF link provided']
686	chugai-pharm	tocilizumab	['vasculitis']	False	['humanized antibody']	/english/ir/pdf/170425ePipeline.pdf	['PDF link provided']
687	chugai-pharm	CIM331	[]	2	['antibody', 'monoclonal']	/english/ir/pdf/170425ePipeline.pdf	['PDF link provided']
688	chugai-pharm	nemolizumab	['dermatitis']	2	['humanized antibody']	/english/ir/pdf/170425ePipeline.pdf	['PDF link provided']
689	chugai-pharm	RG7440	['tumors']	1	['inhibitor']	/english/ir/pdf/170425ePipeline.pdf	['PDF link provided']
690	chugai-pharm	Anti-C5	[]	2	['antibody']	/english/ir/pdf/170425ePipeline.pdf	['PDF link provided']
691	chugai-pharm	codrituzumab	['tumors']	3	['Anti-Glypican-3', 'monoclonal']	/english/ir/pdf/170425ePipeline.pdf	['PDF link provided']
692	chugai-pharm	PCO371	[]	2	['inhibitor']	/english/ir/pdf/170425ePipeline.pdf	['PDF link provided']
693	chugai-pharm	EOS789	['Autoimmune', 'Diseases']	1	[]	/english/ir/pdf/170425ePipeline.pdf	['PDF link provided']
694	chugai-pharm	gantenerumab	['disease']	3	['monoclonal']	/english/ir/pdf/170425ePipeline.pdf	['PDF link provided']
695	chugai-pharm	RG7604	['conjugate', 'tumors']	1	[]	/english/ir/pdf/170425ePipeline.pdf	['PDF link provided']
696	chugai-pharm	Anti-IL-31	['dermatitis']	2	['monoclonal', 'antibody']	/english/ir/pdf/170425ePipeline.pdf	['PDF link provided']
697	chugai-pharm	lebrikizumab	['fibrosis', 'pulmonary', 'Idiopathic']	3	['humanized antibody']	/english/ir/pdf/170425ePipeline.pdf	['PDF link provided']
698	chugai-pharm	atezolizumab	['Prostate', 'Ovarian', 'Breast', 'cancer']	3	['monoclonal', 'antibody']	/english/ir/pdf/170425ePipeline.pdf	['PDF link provided']
699	chugai-pharm	RG7412	['disease']	3	['antibody', 'monoclonal']	/english/ir/pdf/170425ePipeline.pdf	['PDF link provided']
700	chugai-pharm	trastuzumab	['Breast', 'cancer']	3	['humanized antibody']	/english/ir/pdf/170425ePipeline.pdf	['PDF link provided']
701	chugai-pharm	URAT1	['Gout']	2	[]	/english/ir/pdf/170425ePipeline.pdf	['PDF link provided']
702	chugai-pharm	RG7916	['atrophy']	3	['antibody', 'monoclonal']	/english/ir/pdf/170425ePipeline.pdf	['PDF link provided']
703	chugai-pharm	ERY974	['tumors']	1	['inhibitor']	/english/ir/pdf/170425ePipeline.pdf	['PDF link provided']
704	chugai-pharm	RG435	[]	3	[]	/english/ir/pdf/170425ePipeline.pdf	['PDF link provided']
705	chugai-pharm	crenezumab	['disease']	3	['monoclonal']	/english/ir/pdf/170425ePipeline.pdf	['PDF link provided']
706	chugai-pharm	RO5137382	['Prostate', 'cancer']	3	[]	/english/ir/pdf/170425ePipeline.pdf	['PDF link provided']
707	chugai-pharm	emtansine	['lymphoma', 'non-Hodgkin’s', 'Breast', 'cancer', 'conjugate']	3	['Anti-HER2', 'inhibitor']	/english/ir/pdf/170425ePipeline.pdf	['PDF link provided']
708	chugai-pharm	RG3502	['Breast', 'cancer']	3	['antibody', 'monoclonal']	/english/ir/pdf/170425ePipeline.pdf	['PDF link provided']
709	chugai-pharm	obinutuzumab	['non-Hodgkin’s', 'lymphoma']	3	['monoclonal']	/english/ir/pdf/170425ePipeline.pdf	['PDF link provided']
710	chugai-pharm	emicizumab	['A', 'Hemophilia']	3	['antibody']	/english/ir/pdf/170425ePipeline.pdf	['PDF link provided']
711	chugai-pharm	Code4519	[]	Unknown	False	/english/ir/pdf/170425ePipeline.pdf	['PDF link provided']
712	chugai-pharm	RO5424802	['cancer']	False	[]	/english/ir/pdf/170425ePipeline.pdf	['PDF link provided']
713	chugai-pharm	RG7596	['conjugate']	1	['inhibitor', 'MEK']	/english/ir/pdf/170425ePipeline.pdf	['PDF link provided']
714	chugai-pharm	pertuzumab	['Breast', 'cancer']	3	['humanized antibody']	/english/ir/pdf/170425ePipeline.pdf	['PDF link provided']
715	chugai-pharm	Anti-IL-13	['fibrosis', 'pulmonary', 'Idiopathic']	2	['monoclonal']	/english/ir/pdf/170425ePipeline.pdf	['PDF link provided']
716	chugai-pharm	RG6078	['Diseases', 'tumors']	1	['inhibitor', 'antibody']	/english/ir/pdf/170425ePipeline.pdf	['PDF link provided']
717	lily	Emibetuzumab	['Oncology']	2	['humanized antibody']	https://www.lilly.com/pipeline/	[]
718	lily	Adalimumab	['Rheumatoid', 'Arthritis']	3	[]	https://www.lilly.com/pipeline/	[]
719	lily	Adalimumab	[]	3	[]	https://www.lilly.com/pipeline/	[]
720	lily	Adalimumab	['Rheumatoid']	3	[]	https://www.lilly.com/pipeline/	[]
721	lily	Merestinib	['cancer']	2	['tyrosine-kinase inhibitor']	https://www.lilly.com/pipeline/	[]
722	lily	AÃ42	[]	1	['Antibody']	https://www.lilly.com/pipeline/	[]
723	lily	AÃ42	"[""Alzheimer's""]"	1	['Antibody', 'Antibody']	https://www.lilly.com/pipeline/	[]
724	lily	norepinephrine.	[]	2	['chemical substance']	https://www.lilly.com/pipeline/	[]
725	lily	LY3015014	[]	2	['monoclonal', 'Antibody', 'Monoclonal']	https://www.lilly.com/pipeline/	[]
726	lily	LY3015014	[]	2	[]	https://www.lilly.com/pipeline/	[]
727	lily	LY3023414	['Oncology', 'prostate']	2	['Inhibitor)', 'Inhibitor']	https://www.lilly.com/pipeline/	[]
728	lily	LY3023414	['prostate']	2	[]	https://www.lilly.com/pipeline/	[]
729	lily	LY2606368	['Oncology']	2	[]	https://www.lilly.com/pipeline/	[]
730	lily	LY2606368	[]	2	[]	https://www.lilly.com/pipeline/	[]
731	lily	LY3009806	['Oncology']	3	[]	https://www.lilly.com/pipeline/	[]
732	lily	LY3009806	[]	3	[]	https://www.lilly.com/pipeline/	[]
733	lily	LY3202626	"[""Alzheimer's""]"	2	['inhibitor']	https://www.lilly.com/pipeline/	[]
734	lily	LY3202626	"[""Alzheimer's""]"	2	[]	https://www.lilly.com/pipeline/	[]
735	lily	LY3314814	[]	3	[]	https://www.lilly.com/pipeline/	[]
736	lily	LY3314814	"[""Alzheimer's""]"	3	[]	https://www.lilly.com/pipeline/	[]
737	lily	throughApril	[]	False	['Angiotensin converting enzyme inhibitor']	https://www.lilly.com/pipeline/	[]
738	lily	LY3009104	[]	2	[]	https://www.lilly.com/pipeline/	[]
739	lily	LY3009104	['rheumatoid']	2	[]	https://www.lilly.com/pipeline/	[]
740	lily	LY3009104	['dermatitis']	2	[]	https://www.lilly.com/pipeline/	[]
741	lily	LY3009104	['lupus']	2	[]	https://www.lilly.com/pipeline/	[]
742	lily	LY2228820	['Oncology']	2	['inhibitor)']	https://www.lilly.com/pipeline/	[]
743	lily	LY2228820	['ovarian']	2	[]	https://www.lilly.com/pipeline/	[]
744	lily	LY2157299	['Oncology']	2	['inhibitor)']	https://www.lilly.com/pipeline/	[]
745	lily	LY2157299	[]	2	[]	https://www.lilly.com/pipeline/	[]
746	lily	LY3039478	['Oncology']	2	['Inhibitor)', 'inhibitor']	https://www.lilly.com/pipeline/	[]
747	lily	LY3039478	[]	2	[]	https://www.lilly.com/pipeline/	[]
748	lily	Solanezumab	[]	3	['humanized antibody']	https://www.lilly.com/pipeline/	[]
749	lily	LY2140023	[]	1	[]	https://www.lilly.com/pipeline/	[]
750	lily	LY2140023	"[""Alzheimer's"", 'cancer']"	1	[]	https://www.lilly.com/pipeline/	[]
751	lily	baricitinib	['lupus']	2	[]	https://www.lilly.com/pipeline/	[]
752	lily	Edivoxetine	[]	2	['Antidepressant related to fluoxetine']	https://www.lilly.com/pipeline/	[]
753	lily	ixekizumab	[]	3	['humanized antibody']	https://www.lilly.com/pipeline/	[]
754	lily	LY2875358	['Oncology']	2	[]	https://www.lilly.com/pipeline/	[]
755	lily	LY2875358	[]	2	[]	https://www.lilly.com/pipeline/	[]
756	lily	LY2801653	['Oncology']	2	['inhibitor)']	https://www.lilly.com/pipeline/	[]
757	lily	LY2801653	[]	2	[]	https://www.lilly.com/pipeline/	[]
758	lily	LY573144	[]	3	[]	https://www.lilly.com/pipeline/	[]
759	lily	LY573144	['acute']	3	[]	https://www.lilly.com/pipeline/	[]
760	lily	tanezumab	['Chronic', 'osteoarthritis']	3	['humanized antibody']	https://www.lilly.com/pipeline/	[]
761	lily	tanezumab	['chronic', 'cancer']	3	['humanized antibody']	https://www.lilly.com/pipeline/	[]
762	lily	tanezumab	['chronic']	3	['humanized antibody']	https://www.lilly.com/pipeline/	[]
763	lily	LY900014	[]	2	[]	https://www.lilly.com/pipeline/	[]
764	lily	LY900014	['diabetes']	2	[]	https://www.lilly.com/pipeline/	[]
765	lily	LY900014	"[""Alzheimer's"", 'diabetes']"	2	[]	https://www.lilly.com/pipeline/	[]
766	lily	Baricitinib-Treated	['Rheumatoid', 'Arthritis']	False	['tyrosine-kinase inhibitor']	https://www.lilly.com/pipeline/	[]
767	lily	"Peptide"""	[]	1	[]	https://www.lilly.com/pipeline/	[]
768	lily	Tanezumab	[]	3	['humanized antibody']	https://www.lilly.com/pipeline/	[]
769	lily	Tanezumab	['osteoarthritis']	3	['antibody', 'monoclonal']	https://www.lilly.com/pipeline/	[]
770	lily	Tanezumab	['Chronic', 'breast']	3	['humanized antibody']	https://www.lilly.com/pipeline/	[]
771	lily	Tanezumab	['cancer']	3	['humanized antibody']	https://www.lilly.com/pipeline/	[]
772	lily	Tanezumab	['cancer']	3	['antibody', 'monoclonal']	https://www.lilly.com/pipeline/	[]
773	lily	Tanezumab	['chronic']	3	['humanized antibody']	https://www.lilly.com/pipeline/	[]
774	lily	Tanezumab	['chronic']	3	['antibody', 'monoclonal']	https://www.lilly.com/pipeline/	[]
775	lily	PCSK9	[]	2	[]	https://www.lilly.com/pipeline/	[]
776	lily	PCSK9	[]	2	['Monoclonal', 'Antibody']	https://www.lilly.com/pipeline/	[]
777	lily	Mirikizumab	['psoriasis']	2	['humanized antibody']	https://www.lilly.com/pipeline/	[]
778	lily	LY2951742	['chronic']	3	[]	https://www.lilly.com/pipeline/	[]
779	lily	LY2951742	[]	3	[]	https://www.lilly.com/pipeline/	[]
780	lily	CXCR4	[]	2	[]	https://www.lilly.com/pipeline/	[]
781	lily	CXCR4	['Oncology']	2	[]	https://www.lilly.com/pipeline/	[]
782	lily	LY2874455	['Oncology']	2	['Inhibitor']	https://www.lilly.com/pipeline/	[]
783	lily	LY2874455	[]	2	[]	https://www.lilly.com/pipeline/	[]
784	lily	chemokine	[]	2	['chemical substance']	https://www.lilly.com/pipeline/	[]
785	lily	solanezumab	"[""Alzheimer's""]"	3	['humanized antibody']	https://www.lilly.com/pipeline/	[]
786	lily	AZD3293	"[""Alzheimer's""]"	3	[]	https://www.lilly.com/pipeline/	[]
787	lily	IL-21	[]	1	[]	https://www.lilly.com/pipeline/	[]
788	lily	IL-21	['diabetes']	1	['Antibody']	https://www.lilly.com/pipeline/	[]
789	lily	LY2835219	['tumor', 'Oncology']	3	['inhibitor']	https://www.lilly.com/pipeline/	[]
790	lily	LY2835219	['Cancer', 'breast', 'Breast']	3	[]	https://www.lilly.com/pipeline/	[]
791	lily	LY2835219	['tumor']	3	[]	https://www.lilly.com/pipeline/	[]
792	lily	LY2835219	['tumor']	2	['inhibitor']	https://www.lilly.com/pipeline/	[]
793	lily	LY2835219	[]	3	[]	https://www.lilly.com/pipeline/	[]
794	lily	LY2835219	['tumor', 'Oncology']	2	['inhibitor']	https://www.lilly.com/pipeline/	[]
795	lily	ramucirumab	[]	3	[]	https://www.lilly.com/pipeline/	[]
796	lily	DGAT-2	[]	1	['inhibitor']	https://www.lilly.com/pipeline/	[]
797	lily	DGAT-2	[]	1	['inhibitor', 'inhibitor']	https://www.lilly.com/pipeline/	[]
798	lily	LY2062430	[]	3	[]	https://www.lilly.com/pipeline/	[]
799	lily	LY2062430	"[""Alzheimer's""]"	3	[]	https://www.lilly.com/pipeline/	[]
800	lily	galcanezumab	['chronic']	3	['humanized antibody']	https://www.lilly.com/pipeline/	[]
801	lily	galcanezumab	['cancer']	3	['humanized antibody']	https://www.lilly.com/pipeline/	[]
802	lily	LY3337641	[]	2	['inhibitor)']	https://www.lilly.com/pipeline/	[]
803	lily	LY3337641	['rheumatoid']	2	[]	https://www.lilly.com/pipeline/	[]
804	lily	LY3074828	['psoriasis']	2	[]	https://www.lilly.com/pipeline/	[]
805	lily	LY3074828	[]	2	['cytokine']	https://www.lilly.com/pipeline/	[]
806	lily	LY3074828	[]	2	[]	https://www.lilly.com/pipeline/	[]
807	lily	Ralimetinib	[]	2	['tyrosine-kinase inhibitor']	https://www.lilly.com/pipeline/	[]
808	lily	Ralimetinib	['Oncology']	2	['tyrosine-kinase inhibitor']	https://www.lilly.com/pipeline/	[]
809	lily	LY2439821	[]	3	[]	https://www.lilly.com/pipeline/	[]
810	lily	Ramucirumab	['A']	3	[]	https://www.lilly.com/pipeline/	[]
811	lily	Ramucirumab	['Oncology']	3	[]	https://www.lilly.com/pipeline/	[]
812	lily	Ramucirumab	[]	3	[]	https://www.lilly.com/pipeline/	[]
813	lily	Florbenazine	[]	2	['phenothiazine-like antipsychotics']	https://www.lilly.com/pipeline/	[]
814	lily	Florbenazine	"[""Parkinson's"", 'disease']"	2	['phenothiazine-like antipsychotics']	https://www.lilly.com/pipeline/	[]
815	lily	Baricitinib	['Rheumatoid', 'Arthritis']	3	['tyrosine-kinase inhibitor']	https://www.lilly.com/pipeline/	[]
816	lily	Baricitinib	[]	3	['tyrosine-kinase inhibitor']	https://www.lilly.com/pipeline/	[]
817	lily	Baricitinib	['Rheumatoid']	3	['tyrosine-kinase inhibitor']	https://www.lilly.com/pipeline/	[]
818	lily	Baricitinib	['Arthritis']	3	['tyrosine-kinase inhibitor']	https://www.lilly.com/pipeline/	[]
819	lily	Baricitinib	['Rheumatoid', 'Arthritis', 'Disease']	3	['tyrosine-kinase inhibitor']	https://www.lilly.com/pipeline/	[]
820	lily	Baricitinib	['Rheumatoid']	2	['tyrosine-kinase inhibitor']	https://www.lilly.com/pipeline/	[]
821	lily	Baricitinib	['dermatitis']	2	['tyrosine-kinase inhibitor']	https://www.lilly.com/pipeline/	[]
822	lily	LY2510924	['Oncology']	2	['Antagonist']	https://www.lilly.com/pipeline/	[]
823	lily	LY2510924	[]	2	[]	https://www.lilly.com/pipeline/	[]
824	lily	Galcanezumab	[]	3	['monoclonal']	https://www.lilly.com/pipeline/	[]
825	lily	Galcanezumab	['Migraine']	3	['humanized antibody']	https://www.lilly.com/pipeline/	[]
826	lily	Galcanezumabmigraine	[]	3	['humanized antibody']	https://www.lilly.com/pipeline/	[]
827	lily	BI10773	[]	3	[]	https://www.lilly.com/pipeline/	[]
828	lily	BI10773	['chronic', 'heart']	3	[]	https://www.lilly.com/pipeline/	[]
829	lily	BI10773	['Diabetes']	3	[]	https://www.lilly.com/pipeline/	[]
830	lily	dulaglutide	[]	1	[]	https://www.lilly.com/pipeline/	[]
831	lily	IL-23	['psoriasis']	2	['cytokine']	https://www.lilly.com/pipeline/	[]
832	lily	LY2216684	[]	2	[]	https://www.lilly.com/pipeline/	[]
833	alexion	Eculizumab	['Myasthenia']	False	['humanized antibody']	http://www.alexion.com/research-development/pipeline	[]
834	alexion	Eculizumab	['(NMOSD)', 'Neuromyelitis']	False	['humanized antibody']	http://www.alexion.com/research-development/pipeline	[]
835	alexion	Eculizumab	['(NMOSD)', 'respiratory', 'bowel', 'disease', 'loss', 'Neuromyelitis', 'autoimmune']	False	['humanized antibody']	http://www.alexion.com/research-development/pipeline	[]
836	alexion	Eculizumab	['(AMR)']	False	['Antibody']	http://www.alexion.com/research-development/pipeline	[]
837	alexion	Eculizumab	['kidney', 'loss', '(AMR)']	False	['Antibody']	http://www.alexion.com/research-development/pipeline	[]
838	alexion	ALXN1101	['A', 'Deficiency']	False	[]	http://www.alexion.com/research-development/pipeline	[]
839	alexion	ALXN1540	['respiratory', 'heart', 'Crigler-Najjar', 'Syndrome']	False	[]	http://www.alexion.com/research-development/pipeline	[]
840	alexion	ALXN1540	['congenital', 'chronic', 'Crigler-Najjar', 'Syndrome']	False	[]	http://www.alexion.com/research-development/pipeline	[]
841	alexion	ALXN1540	['disease', 'brain']	False	[]	http://www.alexion.com/research-development/pipeline	[]
842	alexion	ALXN1210	['loss', 'PNH']	3	[]	http://www.alexion.com/research-development/pipeline	[]
843	alexion	ALXN1210	['PNH']	3	['antibody']	http://www.alexion.com/research-development/pipeline	[]
844	alexion	ALXN1210	['aHUS']	3	['inhibitor']	http://www.alexion.com/research-development/pipeline	[]
845	alexion	ALXN1210	['aHUS']	3	['antibody']	http://www.alexion.com/research-development/pipeline	[]
846	alexion	ALXN1210	[]	3	[]	http://www.alexion.com/research-development/pipeline	[]
847	alexion	ALXN1210	[]	3	['Inhibitors']	http://www.alexion.com/research-development/pipeline	[]
848	alexion	UGT1A1	['congenital', 'brain']	False	[]	http://www.alexion.com/research-development/pipeline	[]
849	alexion	samalizumab	['Acute']	False	['humanized antibody']	http://www.alexion.com/research-development/pipeline	[]
850	alexion	samalizumab	[]	False	['humanized antibody']	http://www.alexion.com/research-development/pipeline	[]
851	alexion	eculizumab	['aHUS']	False	['inhibitor']	http://www.alexion.com/research-development/pipeline	[]
852	alexion	CD200	['Leukemia']	False	['antibody', 'monoclonal']	http://www.alexion.com/research-development/pipeline	[]
853	alexion	ENPP1	['Arterial', 'loss']	False	[]	http://www.alexion.com/research-development/pipeline	[]
854	alexion	ENPP1	['arterial', 'disease', 'Arterial', 'heart', 'respiratory']	False	[]	http://www.alexion.com/research-development/pipeline	[]
855	alexion	SBC-103	['Mucopolysaccharidosis']	False	[]	http://www.alexion.com/research-development/pipeline	[]
856	alexion	SBC-103	['disease', 'Mucopolysaccharidosis']	False	[]	http://www.alexion.com/research-development/pipeline	[]
857	alexion	Samalizumab	['Tumors']	False	['humanized antibody']	http://www.alexion.com/research-development/pipeline	[]
858	alexion	Samalizumab	['Tumors']	False	['monoclonal', 'antibody']	http://www.alexion.com/research-development/pipeline	[]
859	alexion	Samalizumab	['Leukemia', 'Acute']	False	['humanized antibody']	http://www.alexion.com/research-development/pipeline	[]
860	alexion	Samalizumab	['Leukemia', 'Lymphoma', 'Acute', 'acute']	False	['monoclonal', 'antibody']	http://www.alexion.com/research-development/pipeline	[]
861	lundbeck	Clozapine	['schizophrenia']	False	['chemical substance']	http://investor.lundbeck.com/pipeline.cfm	[]
862	lundbeck	Brexpiprazole	['Schizophrenia']	2	['Proton-pump inhibitor']	http://investor.lundbeck.com/pipeline.cfm	[]
863	lundbeck	Brexpiprazole	['schizophrenia', 'Schizophrenia']	2	['Proton-pump inhibitor']	http://investor.lundbeck.com/pipeline.cfm	[]
864	lundbeck	Brexpiprazole	[]	2	['Proton-pump inhibitor']	http://investor.lundbeck.com/pipeline.cfm	[]
865	lundbeck	Brexpiprazole	['schizophrenia']	2	['Proton-pump inhibitor']	http://investor.lundbeck.com/pipeline.cfm	[]
866	lundbeck	Brexpiprazole	"['disease', ""Alzheimer's""]"	3	['Proton-pump inhibitor']	http://investor.lundbeck.com/pipeline.cfm	[]
867	lundbeck	Brexpiprazole	"['disease', ""Alzheimer's"", 'schizophrenia']"	3	['Proton-pump inhibitor']	http://investor.lundbeck.com/pipeline.cfm	[]
868	lundbeck	AF35700	['Schizophrenia']	3	[]	http://investor.lundbeck.com/pipeline.cfm	[]
869	lundbeck	AF35700	[]	2	[]	http://investor.lundbeck.com/pipeline.cfm	[]
870	lundbeck	AF35700	['schizophrenia', 'Schizophrenia']	2	[]	http://investor.lundbeck.com/pipeline.cfm	[]
871	lundbeck	Aripiprazole	['Schizophrenia']	2	['Proton-pump inhibitor']	http://investor.lundbeck.com/pipeline.cfm	[]
872	lundbeck	Aripiprazole	['Schizophrenia']	3	['Proton-pump inhibitor']	http://investor.lundbeck.com/pipeline.cfm	[]
873	lundbeck	Aripiprazole	[]	3	['Proton-pump inhibitor']	http://investor.lundbeck.com/pipeline.cfm	[]
874	lundbeck	Aripiprazole	"[""Alzheimer's"", 'Bipolar']"	3	['Proton-pump inhibitor']	http://investor.lundbeck.com/pipeline.cfm	[]
875	lundbeck	Aripiprazole	['Bipolar']	3	['Proton-pump inhibitor']	http://investor.lundbeck.com/pipeline.cfm	[]
876	lundbeck	aripiprazole.	['schizophrenia']	3	['Proton-pump inhibitor']	http://investor.lundbeck.com/pipeline.cfm	[]
877	lundbeck	aripiprazole.	['chronic', 'bipolar', 'schizophrenia', 'Bipolar', 'disease', 'psychiatric', 'acute']	3	['Proton-pump inhibitor']	http://investor.lundbeck.com/pipeline.cfm	[]
878	lundbeck	aripiprazole	['Schizophrenia']	2	['Proton-pump inhibitor']	http://investor.lundbeck.com/pipeline.cfm	[]
879	lundbeck	aripiprazole	['chronic', 'schizophrenia', 'Schizophrenia', 'disease', 'brain']	3	['Proton-pump inhibitor']	http://investor.lundbeck.com/pipeline.cfm	[]
880	valeant	Latanoprostene	['Cataract', 'Glaucoma', 'Eye']	False	['Prostaglandin analogue']	http://www.valeant.com/operational-expertise/valeant-united-states/pipeline	[]
881	valeant	IDP-118	['Psoriasis', 'Ocular', 'Eye', 'psoriasis']	False	[]	http://www.valeant.com/operational-expertise/valeant-united-states/pipeline	[]
882	valeant	IDP-121	['Acne', 'Eye', 'Ocular', 'redness']	False	[]	http://www.valeant.com/operational-expertise/valeant-united-states/pipeline	[]
883	valeant	IDP-122	['Psoriasis', 'Acne']	False	[]	http://www.valeant.com/operational-expertise/valeant-united-states/pipeline	[]
884	valeant	Timeline	['Cataract', 'Glaucoma', 'Eye']	False	['chemical substance']	http://www.valeant.com/operational-expertise/valeant-united-states/pipeline	[]
885	valeant	IDP-123	['Psoriasis', 'Acne']	1	[]	http://www.valeant.com/operational-expertise/valeant-united-states/pipeline	[]
886	valeant	IDP-120	['Acne', 'Eye', 'Ocular']	1	[]	http://www.valeant.com/operational-expertise/valeant-united-states/pipeline	[]
887	daiichisankyo	daiichisankyo	['!']	['!']	['!']	http://www.daiichisankyo.com/rd/pipeline/	['Error attempting to reach website!']
888	danippon	danippon	['!']	['!']	['!']	http://www.ds-pharma.com/rd/clinical/pipeline.html	['Error attempting to reach website!']
889	sumitomo	sumitomo	['!']	['!']	['!']	http://www.ds-pharma.com/rd/clinical/pipeline.html	['Error attempting to reach website!']
890	teijin-pharma	teijin-pharma	['!']	['!']	['!']	http://www.teijin-pharma.com/business/research.html	"[""Can't find pipeline or DNE!""]"
